|

Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!

ByPsychedelic Spotlight

Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain

Enjoy!
Links:
Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793

Increased depression in North America:
https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx

https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx

Opioid Overdose In Ontario:
https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080

FDA Greenlights Ketamine:

FDA Green-Lights Ketamine Study for Side Effects of Parkinson’s Disease Treatment

California Bill to Decriminalize Psychedelics Passes Senate Floor:

California Bill To Legalize Possession Of Psychedelics Heads To Senate Floor After Committee Action

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #PsychedelicIndustry

Similar Posts

  • MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock

    Listen, Videos

    MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock

    Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/

    All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call.

    Follow us on Twitter:
    The Psychedelic Investor: @psycInvestor
    James: @Psy_Invest
    Maria: @psy_holy
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    Meet Kevin O’Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami!
    https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64

    COUPON CODE: PSYCHSPOTLIGHT15

    Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

    In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more.

    The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines.

    Some of the questions MindMed is trying to answer are:

    Can Psychedelics treat Mental Health conditions?

    Can Psychedelics treat depression?

    Can Psychedelics treat anxiety?

    Can Psychedelics treat ADHD?

    Can Psychedelics help with Autism?

    Can Psychedelics help treat pain?

    #MindMed #MNMD #MindMedStocks

  • How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more

    Listen, Videos

    Who’s winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now.

    Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions.

    Timestamps:
    0:00 – Intro
    1:34 – What is the clinical trial system?
    2:15 – Preclinical
    3:00 – Phase 0
    3:32 – Phase I
    5:45 – Phase II
    8:26 – Phase III
    10:28 – Phase IV
    11:08 – Who’s winning the race?
    11:16 – MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD
    12:02 – Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360
    12:28 – MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC)
    13:23 – Mydecine (MYCO) and CYBIN (CYBN) following suit

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing by: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Numi #CMPS

  • Interview With Ronan Levy

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast, we catch up with Ronan Levy, Co-Founder and Executive Chairman of Field Trip Health, and discuss the significance behind the company’s recent opening of its psilocybin research and cultivation facility in Jamaica along with the company’s recent listing on the OTCQX.